株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

髄膜炎菌ワクチン:Nimenrix

Nimenrix

発行 Datamonitor Healthcare 商品コード 912153
出版日 ページ情報 英文 13 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.81円で換算しております。
Back to Top
髄膜炎菌ワクチン:Nimenrix Nimenrix
出版日: 2019年09月03日 ページ情報: 英文 13 Pages
概要

当レポートでは、Nimenrix (髄膜炎菌A、C、W135およびY群結合ワクチン) について取り上げ、医薬品の概要、製品プロファイルなどを提供しています。

概要

  • 医薬品の概要
  • 製品プロファイル
  • Nimenrix:髄膜炎菌ワクチン
目次
Product Code: DMKC0182438

Drug Overview

Nimenrix (quadrivalent polysaccharide tetanus toxoid conjugate vaccine; Pfizer) is a conjugated polysaccharide vaccine indicated for active immunization to prevent invasive meningococcal disease (IMD) caused by Neisseria meningitidis (N. meningitidis) serogroups A, C, Y, and W-135 in individuals from the age of six weeks. It induces the production of bactericidal antibodies against capsular polysaccharides of N. meningitidis group A, C, W-135, and Y.

Nimenrix is the only meningococcal vaccine against serotypes A, C, W-135, and Y (MenACWY) recommended for use in infants as early as six weeks of age in the EU. Despite that, it will continue to face significant competition in the European market from Menveo (quadrivalent oligosaccharide diphtheria CRM-197 conjugate vaccine; GlaxoSmithKline), which was approved two years before Nimenrix. As national recommendations restrict the use of MenACWY vaccines to at-risk, usually adult populations, the commercial potential of Nimenrix is limited. Sales of Nimenrix will be further threatened by pipeline vaccine MenABCW-135Y (pentavalent meningococcal conjugate vaccine; GlaxoSmithKline) starting from 2022, if it manages to demonstrate non-inferior immunogenicity against all five strains when compared to marketed vaccines.

TABLE OF CONTENTS

OVERVIEW

  • Drug Overview
  • Product Profiles
  • Nimenrix : Meningococcal vaccines

LIST OF TABLES

  • Table 1: Nimenrix drug profile
  • Table 2: Approval history of Nimenrix for meningococcal vaccination in the five major EU markets
  • Table 3: Late-phase trials of Nimenrix for meningococcal vaccination
  • Table 4: Nimenrix for meningococcal disease - SWOT analysis
Back to Top